Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-05-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-0292PMID 24874833PMCID PMC4119496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

  2014cited by this paper
• A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

  2013cited by this paper
• Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

  2013cited by this paper
• Overcoming mutation-based resistance to antiandrogens with rational drug design

  2013cited by this paper
• An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation*

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012influential reference
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

  2011cited by this paper
• Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

  2011influential reference
• Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells*

  2011cited by this paper
• Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

  2011cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009influential reference
• Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

  2008cited by this paper
• 17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response

  2008cited by this paper
• Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

  2008cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008cited by this paper
• Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

  2008cited by this paper
• Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design*

  2007cited by this paper
• Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

  2006cited by this paper
• Structural basis for antagonism and resistance of bicalutamide in prostate cancer

  2005cited by this paper
• Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

  2005influential reference
• Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor*

  2005cited by this paper
• The Androgen Axis in Recurrent Prostate Cancer

  2004cited by this paper
• Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.

  2004cited by this paper
• Recruitment of β-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells

  2004cited by this paper
• Formation of the androgen receptor transcription complex.

  2002cited by this paper
• Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.

  2002cited by this paper
• Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor*

  2002cited by this paper
• Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels.

  2000cited by this paper
• High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

  1998cited by this paper
• Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

  1997cited by this paper
• Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

  1992cited by this paper
• Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells.

  1991cited by this paper

• Cell‐ELISA‐Based High‐Throughput Screening Leads to the Discovery of Androgen Receptor Degraders to Conquer Castration‐Resistant Prostate Cancer

  2025cites this paper
• Structure, Inhibitors, and Biological Function in Nervous System and Cancer of Ubiquitin-Specific Protease 46

  2024influential citation
• Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer

  2024cites this paper
• Androgen receptor inhibitors in treating prostate cancer

  2024cites this paper
• Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective

  2024cites this paper
• Targeting sex steroid biosynthesis for breast and prostate cancer therapy

  2023cites this paper
• Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

  2023cites this paper
• The androgen receptor.

  2023cites this paper
• Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation

  2023cites this paper
• Synthesis of hydrocortisone esters targeting androgen and glucocorticoid receptors in prostate cancer in vitro.

  2023cites this paper
• Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models

  2022influential citation
• From Therapy Resistance to Targeted Therapies in Prostate Cancer

  2022cites this paper
• Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective

  2022cites this paper
• An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer

  2021cites this paper
• Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on

  2021cites this paper
• Androgen metabolism in castration-resistant prostate cancer

  2021cites this paper
• Synthesis of dihydrotestosterone derivatives modified in the A-ring with (hetero)arylidene, pyrazolo[1,5-a]pyrimidine and triazolo[1,5-a]pyrimidine moieties and their targeting of the androgen receptor in prostate cancer.

  2021cites this paper
• Design, Synthesis and Biological Evaluation of Steroidal Glycoconjugates as Potential Antiproliferative Agents

  2021cites this paper
• Nuclear receptors: lipid and hormone sensors with essential roles in the control of cancer development.

  2020cites this paper
• Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin

  2020cites this paper
• A role of heme degradation pathway in shaping prostate inflammatory responses and lipid metabolism.

  2020cites this paper
• Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

  2019cites this paper
• Small Non-Coding RNAs Derived from Eukaryotic Ribosomal RNA

  2019cites this paper
• Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: a Survey on Chemical Structures Binding this Fast-Mutating Target.

  2019cites this paper
• Title : A novel small molecule targets androgen receptor and its splice variants in 1 castration-resistant prostate cancer

  2019cites this paper
• Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

  2019cites this paper
• A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

  2019cites this paper
• Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

  2019cites this paper
• Nuclear receptors: recent drug discovery for cancer therapies.

  2019cites this paper
• Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer.

  2018cites this paper
• The potential of AR-V7 as a therapeutic target

  2018cites this paper
• Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor

  2018cites this paper
• Comparison of [17(20)E]‐21‐Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth

  2018cites this paper
• The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

  2018cites this paper
• Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

  2018cites this paper
• Role of Androgen Receptor in Prostate Cancer: A Review

  2018cites this paper
• Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges

  2018cites this paper
• Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen‐dependent and castration‐resistant prostate cancer cells

  2018cites this paper
• Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC

  2018cites this paper
• Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer

  2018cites this paper
• Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

  2018cites this paper
• Androgen deprivation and immunotherapy for the treatment of prostate cancer.

  2017cites this paper
• A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

  2017cites this paper
• Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.

  2017cites this paper
• Response: letter to the editor

  2017cites this paper
• Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy.

  2017cites this paper
• Clinical relevance of androgen receptor alterations in prostate cancer

  2017cites this paper
• Small-Molecule Modulation of Protein Homeostasis.

  2017cites this paper
• Determination of Novel Metabolites of Therapeutic Agents used in the Treatment of Castration-Resistant Prostate Cancer

  2017cites this paper
• Darwinian Selection in Prostate Cancer and Medical Treatment

  2017cites this paper
• Targeted LC–MS Quantification of Androgens and Estrogens for Biomarker Development

  2017cites this paper
• Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model

  2017cites this paper
• Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action

  2017cites this paper
• Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

  2017cites this paper
• Androgen receptor splice variants and prostate cancer: From bench to bedside

  2017influential citation
• Non-Genomic Actions of the Androgen Receptor in Prostate Cancer

  2017cites this paper
• Prostate cancer: The influence of steroid metabolism on CYP17A1 inhibitor activity

  2017cites this paper
• Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

  2017cites this paper
• Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1

  2017cites this paper
• Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.

  2017influential citation
• C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer.

  2017cites this paper
• Emerging data on androgen receptor splice variants in prostate cancer.

  2016cites this paper
• Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer

  2016cites this paper
• Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

  2016cites this paper
• What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer

  2016cites this paper
• Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer

  2016influential citation
• ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

  2016cites this paper
• Targeting persistent androgen receptor signaling in castration-resistant prostate cancer

  2016cites this paper
• Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic

  2016cites this paper
• Utility of novel androgen receptor therapies in the real world: A nuanced approach.

  2016cites this paper
• Galeterone for the treatment of advanced prostate cancer: the evidence to date

  2016cites this paper
• Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer

  2016cites this paper
• Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer

  2016cites this paper
• Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.

  2016cites this paper
• Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach.

  2016cites this paper
• Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic

  2016cites this paper
• Design And Synthesis Of Enzalutamide-Isothiocyanate Hybrid Drug As Anti-Prostate Cancer Agent

  2016cites this paper
• Androgen receptor variation affects prostate cancer progression and drug resistance.

  2016cites this paper
• Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer

  2016influential citation
• The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

  2015cites this paper
• Loss of Wave1 gene defines a subtype of lethal prostate cancer

  2015cites this paper
• AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

  2015cites this paper
• Regulation of AR Degradation and Function by Ubiquitylation

  2015cites this paper
• Identification of novel androgen receptor inhibitors for the treatment of castration resistant prostate cancer

  2015cites this paper
• Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance

  2015cites this paper
• Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.

  2015cites this paper
• Persistent androgen receptor addiction in castration-resistant prostate cancer

  2015cites this paper
• Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo

  2015cites this paper
• Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

  2015cites this paper
• Androgen metabolic pathway involved in current and emerging treatment for men with castration resistant prostate cancer: intraprostatic androgens as therapeutic targets and endocrinological biomarkers.

  2014cites this paper